Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online September 15, 2025.
Article Versions
- Latest version (August 1, 2025 - 04:00).
- You are currently viewing a Latest version of this article (September 15, 2025 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2025 The Journal of Rheumatology
Author Information
- Hugues Allard-Chamard and
- Proton Rahman
- H. Allard-Chamard, MD, PhD, Division of Rheumatology, Faculté de médecine et des sciences de la santé de l'Université de Sherbrooke et Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada.
- P. Rahman, MD, St. Clare's Mercy Hospital, St. John's, Newfoundland and Labrador, Canada.
-
CONTRIBUTIONS: HAC and PR collaborated to conceptualize this review, drafted the original manuscript, and performed revisions and edits.
FUNDING: Funding for PR was provided by the Catherine and James Spinney Foundation and the Atlantic Canada Opportunities Agency Atlantic Innovation Fund (ACOA-AIF). Funding for HAC was provided by the Chaire André-Lussier de rhumatologie, the Canadian Institutes of Health Research, and the Research Scholars - Junior 1 grant from FRQS.
COMPETING INTERESTS: PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, and Pfizer; and research grants from Janssen and Novartis. HAC has received consulting fees from AbbVie, Amgen, AstraZeneca, Celltrion, Eli Lilly, GSK, Hoffmann-La Roche, Janssen, Fresenius Kabi, Novartis, Pfizer, Sandoz, Sobi; and received research grants from AstraZeneca, Eli Lilly, Fresenius Kabi, and Pfizer.
Accepted for publication July 21, 2025.
- Address correspondence to Dr. P. Rahman, St. Clare's Mercy Hospital, 154 Lemarchant Rd, St. John's, NL A1C 5B8, Canada. Email: prahman{at}mun.ca.
